PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Completed · Phase 1

Conditions studied: Neoplasm of Uncertain Malignant Potential, Unspecified Childhood Solid Tumor, Protocol Specific

In brief

RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b in treating young patients with plexiform neurofibroma.

Key facts

Study ID

NCT00253474

Run by

National Institutes of Health Clinical Center (CC)

People needed

36

Starts

2005-09-01

Expected to finish

2011-01-01

Last updated by the study team

2012-03-29

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's National Medical Center — Washington D.C., District of Columbia, United States
• Children's Memorial Hospital - Chicago — Chicago, Illinois, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
• Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.